美国 · SEC FORM 4
Century Therapeutics, Inc.
IPSC · Nasdaq · CIK 0001850119 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
17 同一窗口内观察到的 Form 4 交易行
10 sales · 7 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-22 · Cowan Chad.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 29,218,775
- 上期报告
- 29,354,630
- 日均成交量
- 573,911
- 回补天数
- 50.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | Cowan Chad | 买入 (P) | Common Stock | 58,060 | USD 0.85 | USD 49,351 | SEC 申报 ↗ |
| 2025-12-12 | Pfeiffenberger Brent | 买入 (P) | Common Stock | 52,000 | USD 0.58 | USD 30,160 | SEC 申报 ↗ |
| 2025-11-19 | Pfeiffenberger Brent | 买入 (P) | Common Stock | 35,000 | USD 0.50 | USD 17,500 | SEC 申报 ↗ |
| 2024-09-12 | Quimi Daphne | 买入 (P) | Common Stock | 5,000 | USD 1.53 | USD 7,650 | SEC 申报 ↗ |
| 2021-06-22 | Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC | 买入 (P) | Common Stock | 100,000 | USD 20.00 | USD 2,000,000 | SEC 申报 ↗ |
| 2021-06-22 | BAYER AKTIENGESELLSCHAFT; Bayer World Investments B.V. | 买入 (P) | Common Stock | 750,000 | USD 20.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2021-06-22 | Casdin Eli | 买入 (P) | Common Stock | 750,000 | USD 20.00 | USD 15,000,000 | SEC 申报 ↗ |
Form 4 申报证据
41 transaction lines in the latest 365-day window; 132 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Russotti Gregory | 卖出 (S) | Common Stock | 2,587 | USD 1.93 | USD 4,993 | SEC 申报 ↗ |
| 2026-09-14 | Carr Douglas | 卖出 (S) | Common Stock | 1,658 | USD 1.93 | USD 3,200 | SEC 申报 ↗ |
| 2026-09-11 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 13,850 | USD 1.94 | USD 26,869 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Russotti Gregory | 卖出 (S) | Common Stock | 2,587 | USD 1.93 | USD 4,993 | SEC 申报 ↗ |
| 2026-09-14 | Carr Douglas | 卖出 (S) | Common Stock | 1,658 | USD 1.93 | USD 3,200 | SEC 申报 ↗ |
| 2026-09-11 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 13,850 | USD 1.94 | USD 26,869 | SEC 申报 ↗ |
| 2026-09-08 | Russotti Gregory | 卖出 (S) | Common Stock | 534 | USD 2.05 | USD 1,095 | SEC 申报 ↗ |
| 2026-09-08 | Carr Douglas | 卖出 (S) | Common Stock | 254 | USD 2.05 | USD 521 | SEC 申报 ↗ |
| 2026-09-04 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 463 | USD 2.11 | USD 977 | SEC 申报 ↗ |
| 2026-08-14 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 31,172 | USD 1.92 | USD 59,850 | SEC 申报 ↗ |
| 2026-08-03 | Carr Douglas | 卖出 (S) | Common Stock | 275 | USD 1.98 | USD 544 | SEC 申报 ↗ |
| 2026-06-12 | Russotti Gregory | 卖出 (S) | Common Stock | 2,584 | USD 2.23 | USD 5,762 | SEC 申报 ↗ |
| 2026-06-12 | Carr Douglas | 卖出 (S) | Common Stock | 1,654 | USD 2.23 | USD 3,688 | SEC 申报 ↗ |
| 2026-06-11 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 13,849 | USD 2.24 | USD 31,022 | SEC 申报 ↗ |
| 2026-06-11 | Cowan Chad | 代扣税 (F) | Common Stock | 358 | USD 2.24 | USD 802 | SEC 申报 ↗ |
| 2026-06-08 | Russotti Gregory | 卖出 (S) | Common Stock | 524 | USD 2.11 | USD 1,106 | SEC 申报 ↗ |
| 2026-06-08 | Carr Douglas | 卖出 (S) | Common Stock | 249 | USD 2.11 | USD 525 | SEC 申报 ↗ |
| 2026-06-05 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 463 | USD 2.13 | USD 986 | SEC 申报 ↗ |
| 2026-05-15 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 31,172 | USD 2.34 | USD 72,942 | SEC 申报 ↗ |
| 2026-05-04 | Carr Douglas | 卖出 (S) | Common Stock | 264 | USD 2.34 | USD 618 | SEC 申报 ↗ |
| 2026-04-01 | Cowan Chad | 代扣税 (F) | Common Stock | 1,365 | USD 2.19 | USD 2,989 | SEC 申报 ↗ |
| 2026-03-12 | Russotti Gregory | 卖出 (S) | Common Stock | 10,076 | USD 2.55 | USD 25,694 | SEC 申报 ↗ |
| 2026-03-12 | Carr Douglas | 卖出 (S) | Common Stock | 7,043 | USD 2.55 | USD 17,960 | SEC 申报 ↗ |
| 2026-03-11 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 55,397 | USD 2.73 | USD 151,234 | SEC 申报 ↗ |
| 2026-03-11 | Cowan Chad | 代扣税 (F) | Common Stock | 1,431 | USD 2.73 | USD 3,907 | SEC 申报 ↗ |
| 2026-03-09 | Russotti Gregory | 卖出 (S) | Common Stock | 479 | USD 2.54 | USD 1,217 | SEC 申报 ↗ |
| 2026-03-09 | Carr Douglas | 卖出 (S) | Common Stock | 247 | USD 2.54 | USD 627 | SEC 申报 ↗ |
| 2026-03-06 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 463 | USD 2.56 | USD 1,185 | SEC 申报 ↗ |
| 2026-02-13 | Pfeiffenberger Brent | 代扣税 (F) | Common Stock | 31,172 | USD 1.75 | USD 54,551 | SEC 申报 ↗ |
| 2026-02-03 | Carr Douglas | 卖出 (S) | Common Stock | 323 | USD 1.82 | USD 588 | SEC 申报 ↗ |
| 2026-02-02 | Russotti Gregory | 奖励／授予 (A) | Common Stock | 135,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-02 | Pfeiffenberger Brent | 奖励／授予 (A) | Common Stock | 475,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-02 | Cowan Chad | 奖励／授予 (A) | Common Stock | 135,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | IPSC |
| CIK | 0001850119 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 132 transaction lines from 2021-06-22 to 2026-09-14 7 P purchase lines · 63 S sale lines · 62 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.